Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden

Fig. 1

Analysis of RCB-TILs status and outcome in breast cancer (Disease Free Survival, DFS). Survival was analyzed according to RCB-TILs. DFS after NAC was significantly longer for RCB-TILs-positive patients than for RCB-TILs-negative patients in all patients (p < 0.001, log-rank) (a), TNBC patients (p < 0.001, log-rank) (b), HER2BC patients (p = 0.007, log-rank) (c), and HRBC patients (p = 0.026, log-rank) (d)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us